Fundamental Analysis of BioCryst Pharmaceuticals Inc - Growth / Value Index
BCRX - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 7.81
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -5.95 | -5.11 | -12.19 % | |
| Price to Book | -1.71 | 3.39 | 188.86 % | 3.84 |
| Price to Sales | 3.49 | 3.80 | -8.49 % | |
| Enterprise Value to EBITDA Multiple | -26.28 | -15.52 | -45.28 % |
BCRX - Profitability Highlights
Profitability Analysis
Reasonable Dividend Yield of 3.71 %
Steady Growth in EPS for last four quarters
Tsr Profitability Index - Very Poor Score of 5.00
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 0 | -66.44 | 0 % | -10.50 |
| Return On Asset | -602.27 | -45.72 | -1.76 % | -7.56 |
| Net Profit Margin | -58.69 | -74.43 | 18.43 % | -38.14 |
| Operating Profit Margin | -25.26 | -33.81 | 38.32 % | -15.62 |
| EBITDA Margin | -21.66 | -39.24 | 27.03 % | -15.62 |
Highlights
| Market Cap | 1296.05 M |
| Enterprise Value | 2022.88 M |
| Price/Book TTM | -1.71 |
| Outstanding Share | 206376 K |
| Float/ Outstanding Share | 92.69% |
| Dividend Yield | 3.71 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 3.00 |
| Altman Z Score | 0.882 |
| Sloan Ratio | -0.244 |
| Peter Lynch Fair Value | 0 |
BCRX - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Tsr Growth Index - Very Poor Score of 17.66
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 355395 K | 17.25 % | 0.685 % |
| Gross Profit | 350407 K | 18.09 % | 0.292 % |
| EBITDA | -76970.00 K | 14.44 % | 60.55 % |
| Net Profit | -208585.00 K | 4.36 % | 42.69 % |
| EPS | -1.06 | 10.87 % | NA |
BCRX - Stability Highlights
Stability Analysis
Tsr Stability Index - Very Poor Score of 10.94
Altman Z Score of 0.175 suggest high risk
Company has high debt burden
Company is unable to generate enough free cash to support the business.
Interest Coverage of -1.15
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 2.35 | 565.50 % | 2.42 |
| Cash Ratio | 0.738 | -81.66 % | |
| Quick Ratio | 3.12 | -32.77 % | 3.48 |
| Shareholders Equity | 68.81 | 126.02 % | |
| Debt to EBITDA | -6.72 | -33.05 % |
Historical Valuation Ratios of BioCryst Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of BioCryst Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of BioCryst Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of BioCryst Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)